iSpecimen Inc. filed a Form 10-Q with the SEC on November 17, 2026, covering the quarterly period ended September 30, 2026, disclosing continued operating losses, two PIPE financing rounds, and a 1-for-40 reverse stock split completed in April 2026.
Key Highlights
- Net loss of $5,850,026 for the nine months ended September 30, 2026, compared to a net loss of $5,486,287 for the same period in 2025, according to the filing.
- Revenue of $551,983 for the nine months ended September 30, 2026, down from $1,877,237 in the nine months ended September 30, 2025.
- Two PIPE financing transactions raised a combined $7,500,000 in gross proceeds during the period, with $2,500,000 closed in the second quarter and $5,000,000 closed in the third quarter.
- 1-for-40 reverse stock split was effected on April 27, 2026, with all share and per-share figures in the filing reflecting this retroactively.
- Cash and cash equivalents of $5,556,914 as of September 30, 2026, compared to $6,880,835 at December 31, 2025.
- Accumulated deficit of $88,200,175 as of September 30, 2026, up from $82,350,149 at December 31, 2025.
- 5,789,013 shares of common stock were issued and outstanding as of November 16, 2026, per the filing cover page.
iSpecimen's Financial Position and Operating Results for the Third Quarter of 2026
According to the Form 10-Q filed on NASDAQ:ISPC for the quarterly period ended September 30, 2026, iSpecimen Inc. reported a net loss of $2,211,994 for the three months ended September 30, 2026, compared to a net loss of $2,780,648 for the same quarter in 2025. For the nine-month period, the company reported a net loss of $5,850,026 versus $5,486,287 in the prior-year period. Revenue for the third quarter of 2026 was $244,034, compared to $106,592 in the third quarter of 2025, while nine-month revenue fell to $551,983 from $1,877,237 year over year.
Total operating expenses for the nine months ended September 30, 2026, were $6,650,580, compared to $8,167,274 for the same period in 2025, the filing disclosed. The largest expense category for the nine-month period was sales and marketing at $3,466,709, followed by general and administrative expenses of $1,653,802. The company reported a loss from operations of $6,098,597 for the nine months ended September 30, 2026.
The filing disclosed two separate issuances of common stock in connection with PIPE financings during the period: $2,500,000 in the second quarter, net of $215,000 in offering costs, and $5,000,000 in the third quarter, net of $456,100 in offering costs. As of September 30, 2026, total stockholders' equity stood at $4,068,439, up from $3,088,231 at December 31, 2025. The company's balance sheet reflected internally developed software, net, of $3,106,181 at September 30, 2026, compared to $1,270,017 at December 31, 2025. All share figures in the financial statements reflect the retroactive effect of the 1-for-40 reverse stock split effected on April 27, 2026, as noted in the filing.
What Was Disclosed
iSpecimen Inc. disclosed its unaudited condensed financial statements for the quarter and nine months ended September 30, 2026, reporting a nine-month net loss of $5,850,026, reduced total operating expenses, two PIPE financings totaling $7,500,000 gross, and a 1-for-40 reverse stock split completed on April 27, 2026.



Please wait processing your request...